Stockscreener 앱 받기
44.65
6.34%
-3.02
시장 영업 전:
44.60
-0.05
-0.11%
전일 마감가:
$47.67
열려 있는:
$48
하루 거래량:
1.73M
Relative Volume:
1.30
시가총액:
$3.59B
수익:
$541.74M
순이익/손실:
$88.01M
주가수익비율:
41.11
EPS:
1.0862
순현금흐름:
$155.34M
1주 성능:
-3.10%
1개월 성능:
+4.98%
6개월 성능:
+38.15%
1년 성능:
+23.89%
1일 변동 폭
$44.09
$48.84
1주일 범위
$44.09
$48.84
52주 변동 폭
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
44.65 | 3.65B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Underweight |
| 2025-10-20 | 개시 | Canaccord Genuity | Hold |
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
ETFs Investing in Veracyte, Inc. Stocks - TradingView
Preferred dividends of Veracyte, Inc. – HAN:12V - TradingView
Veracyte, Inc. Cash Flow – HAN:12V - TradingView
Veracyte, Staar Surgical, Corning - TradingView
Veracyte’s Decipher test shows predictive value in prostate cancer - Investing.com
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation - marketscreener.com
For 44% with low scores, added hormone therapy showed no statistically significant benefit against 10-year cancer spread. - Stock Titan
Veracyte Inc. R (12V.MU) Q1 FY2026 earnings call transcript - Yahoo Finance
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 - The Manila Times
Eight studies will examine who with prostate cancer may benefit from more treatment - Stock Titan
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? - Yahoo Finance
Form 144 VERACYTE For: 25 September By Investing.com - Investing.com South Africa
Form 144 VERACYTE For: 25 September - Investing.com India
Veracyte stock rises 10.77 percent toward its yearly high - AD HOC NEWS
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Eastern Progress
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - GuruFocus
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Understanding Momentum Shifts in (VCYT) - Stock Traders Daily
Veracyte global chief commercial off. John Leite sells $160,600 stock By Investing.com - Investing.com Canada
Form 4 Veracyte Inc For: 23 September - Investing.com India
Insider Sell: Global Chief Commercial Officer John Leite Sells 4 - GuruFocus
Veracyte global chief commercial off. John Leite sells $160,600 stock - Investing.com
Form 4 Veracyte Inc For: 23 September By Investing.com - Investing.com Australia
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - Benzinga
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52 - GuruFocus
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144 - Stock Titan
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow - ChartMill
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each - Kalkine Media
Veracyte (VCYT) Dropped, But What Is Driving Attention Now? - simplywall.st
Director Jens Holstein Sells 5,000 Shares of Veracyte (VCYT) - GuruFocus
A Look at Veracyte Inc (VCYT) After 4.1% Decline -- GF Value $39 - GuruFocus
Veracyte Director Jens Holstein Executes Sale of 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Veracyte (VCYT) director offloads 5,000 shares under plan - Stock Titan
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating - Moomoo
Veracyte Adds Another Stream to Bladder Franchise, UBS Says - marketscreener.com
Veracyte at Morgan Stanley conference: growth, deals and new tests By Investing.com - Investing.com Nigeria
Veracyte at Morgan Stanley conference: growth, deals and new tests - Investing.com
Needham reiterates Veracyte stock rating at Buy on genomics deal By Investing.com - Investing.com Nigeria
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Needham reiterates Veracyte stock rating at Buy on genomics deal - Investing.com
Veracyte acquires Convergent Genomics for up to $180 million By Investing.com - Investing.com Australia
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Veracyte acquires Convergent Genomics for up to $180 million - Investing.com
Veracyte Buys Convergent Genomics - marketscreener.com
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veracyte Inc 주식 (VCYT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
0.99%
0.56%
자본화:
|
볼륨(24시간):